Free Trial
→ Peptide Company Lands Exclusive MMA Wellness Partnership (From The Tomorrow Investor) (Ad)tc pixel Free NRIX Stock Alerts

Nurix Therapeutics (NRIX) Financials

Nurix Therapeutics logo
$16.00 -0.18 (-1.11%)
Closing price 04:00 PM Eastern
Extended Trading
$15.95 -0.05 (-0.31%)
As of 07:14 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Compare
Annual Income Statements for Nurix Therapeutics

Annual Income Statements for Nurix Therapeutics

This table shows Nurix Therapeutics' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2019 2020 2021 2022 2023 2024 2025
Period end date 11/30/2019 11/30/2020 11/30/2021 11/30/2022 11/30/2023 11/30/2024 11/30/2025
Net Income / (Loss) Attributable to Common Shareholders		 -22 -43 -117 -180 -144 -194 -264
Consolidated Net Income / (Loss)		 -22 -43 -117 -180 -144 -194 -264
Net Income / (Loss) Continuing Operations		 -22 -43 -117 -180 -144 -194 -264
Total Pre-Tax Income 		-21 -64 -117 -180 -144 -193 -264
Total Operating Income		 -22 -65 -118 -184 -155 -213 -286
Total Gross Profit		 31 18 30 39 77 55 84
Total Revenue		 31 18 30 39 77 55 84
Operating Revenue		 31 18 30 39 77 55 84
Total Cost of Revenue		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Operating Expenses		 53 83 148 222 232 268 370
Selling, General & Admin Expense		 8.33 16 31 38 43 46 53
Research & Development Expense		 45 66 116 184 189 222 317
Total Other Income / (Expense), net		 0.78 1.21 0.82 3.51 11 20 22
Interest & Investment Income		 0.78 1.21 0.82 3.51 11 20 22
Income Tax Expense		 0.24 -21 0.13 0.00 0.00 0.27 0.76
Basic Earnings per Share		 ($6.59) ($2.76) ($2.73) ($3.71) ($2.65) ($2.88) ($3.05)
Weighted Average Basic Shares Outstanding		 3.29M 15.67M 42.90M 48.61M 54.34M 67.12M 86.67M
Diluted Earnings per Share		 ($6.59) ($2.76) ($2.73) ($3.71) ($2.65) ($2.88) ($3.05)
Weighted Average Diluted Shares Outstanding		 3.29M 15.67M 42.90M 48.61M 54.34M 67.12M 86.67M
Weighted Average Basic & Diluted Shares Outstanding		 3.29M 15.67M 42.90M 47.27M 48.89M 75.89M 102.84M
Cash Dividends to Common per Share		 $0.00 $0.00 - - - $0.00 $0.00

Quarterly Income Statements for Nurix Therapeutics

This table shows Nurix Therapeutics' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 8/31/2023 11/30/2023 2/29/2024 5/31/2024 8/31/2024 11/30/2024 2/28/2025 5/31/2025 8/31/2025 11/30/2025 2/28/2026
Net Income / (Loss) Attributable to Common Shareholders		 -37 -42 -42 -45 -49 -59 -56 -43 -86 -78 -87
Consolidated Net Income / (Loss)		 -37 -42 -42 -45 -49 -59 -56 -43 -86 -78 -87
Net Income / (Loss) Continuing Operations		 -37 -42 -42 -45 -49 -59 -56 -43 -86 -78 -87
Total Pre-Tax Income 		-37 -42 -41 -44 -49 -59 -56 -43 -86 -78 -87
Total Operating Income		 -40 -45 -45 -49 -55 -65 -63 -48 -91 -83 -92
Total Gross Profit		 18 15 17 12 13 13 18 44 7.89 14 6.25
Total Revenue		 18 15 17 12 13 13 18 44 7.89 14 6.25
Operating Revenue		 18 - 17 12 13 - 18 44 7.89 14 6.25
Total Cost of Revenue		 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00
Total Operating Expenses		 58 60 62 61 67 78 81 92 99 97 99
Selling, General & Admin Expense		 11 11 12 12 12 11 12 14 13 14 15
Research & Development Expense		 48 50 50 49 55 67 70 78 86 83 84
Total Other Income / (Expense), net		 3.03 3.38 3.79 4.08 5.74 6.12 6.51 5.62 4.96 4.87 5.32
Interest & Investment Income		 3.03 3.38 3.79 4.08 5.74 6.12 6.51 5.62 4.96 4.87 5.32
Basic Earnings per Share		 ($0.68) ($0.77) ($0.76) ($0.71) ($0.67) ($0.74) ($0.67) ($0.52) ($1.03) ($0.83) ($0.79)
Weighted Average Basic Shares Outstanding		 54.39M 54.34M 54.90M 62.38M 72.78M 67.12M 83.56M 83.88M 84.16M 86.67M 110.07M
Diluted Earnings per Share		 ($0.68) ($0.77) ($0.76) ($0.71) ($0.67) ($0.74) ($0.67) ($0.52) ($1.03) ($0.83) ($0.79)
Weighted Average Diluted Shares Outstanding		 54.39M 54.34M 54.90M 62.38M 72.78M 67.12M 83.56M 83.88M 84.16M 86.67M 110.07M
Weighted Average Basic & Diluted Shares Outstanding		 48.50M 48.89M 49.15M 64.41M 70.84M 75.89M 76.24M 76.45M 76.88M 102.84M 103.41M
Cash Dividends to Common per Share		 - - $0.00 - - - $0.00 - - - $0.00

Annual Cash Flow Statements for Nurix Therapeutics

This table details how cash moves in and out of Nurix Therapeutics' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2019 2020 2021 2022 2023 2024 2025
Period end date 11/30/2019 11/30/2020 11/30/2021 11/30/2022 11/30/2023 11/30/2024 11/30/2025
Net Change in Cash & Equivalents		 9.23 85 -39 -15 -9.85 55 137
Net Cash From Operating Activities		 0.60 -0.08 -84 -160 -81 -173 -249
Net Cash From Continuing Operating Activities		 0.60 -0.08 -84 -160 -81 -173 -249
Net Income / (Loss) Continuing Operations		 -22 -43 -117 -180 -144 -194 -264
Consolidated Net Income / (Loss)		 -22 -43 -117 -180 -144 -194 -264
Depreciation Expense		 2.35 2.18 2.79 5.35 7.53 9.32 8.74
Amortization Expense		 -0.11 0.27 5.00 5.89 0.70 -4.18 -0.21
Non-Cash Adjustments To Reconcile Net Income		 0.51 -3.20 16 28 34 34 38
Changes in Operating Assets and Liabilities, net		 20 44 9.11 -19 20 -18 -32
Net Cash From Investing Activities		 8.50 -254 -108 27 68 -258 148
Net Cash From Continuing Investing Activities		 8.50 -254 -108 27 68 -258 148
Purchase of Property, Plant & Equipment		 -1.65 -4.55 -5.66 -12 -8.40 -9.27 -14
Purchase of Investments		 -9.35 -275 -348 -239 -246 -708 -456
Sale and/or Maturity of Investments		 20 25 246 279 323 460 618
Net Cash From Financing Activities		 0.13 339 154 117 3.22 486 239
Net Cash From Continuing Financing Activities		 0.13 339 154 117 3.22 486 239
Repurchase of Preferred Equity		 -0.02 - -0.00 0.00 0.00 -0.02 0.00
Issuance of Common Equity		 0.00 218 152 116 2.23 481 237
Other Financing Activities, net		 0.14 0.97 1.67 1.08 0.99 5.06 1.65

Quarterly Cash Flow Statements for Nurix Therapeutics

This table details how cash moves in and out of Nurix Therapeutics' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 8/31/2023 11/30/2023 2/29/2024 5/31/2024 8/31/2024 11/30/2024 2/28/2025 5/31/2025 8/31/2025 11/30/2025 2/28/2026
Net Change in Cash & Equivalents		 -17 12 -4.81 67 -18 11 -34 8.34 -5.76 169 -176
Net Cash From Operating Activities		 -41 27 -42 -40 -42 -49 -61 -63 -57 -68 -72
Net Cash From Continuing Operating Activities		 -41 27 -42 -40 -42 -49 -61 -63 -57 -68 -72
Net Income / (Loss) Continuing Operations		 -37 -42 -42 -45 -49 -59 -56 -43 -86 -78 -87
Consolidated Net Income / (Loss)		 -37 -42 -42 -45 -49 -59 -56 -43 -86 -78 -87
Depreciation Expense		 1.95 1.93 2.05 2.33 2.39 2.55 2.35 2.24 2.03 2.12 2.20
Amortization Expense		 -0.21 -0.15 -0.09 -0.40 -1.95 -1.74 -1.78 0.15 0.78 0.64 -0.40
Non-Cash Adjustments To Reconcile Net Income		 8.89 8.04 7.82 8.85 9.04 8.54 8.72 10 9.77 9.18 9.56
Changes in Operating Assets and Liabilities, net		 -15 59 -10 -5.94 -2.70 0.45 -14 -32 16 -1.55 3.90
Net Cash From Investing Activities		 23 -14 36 -131 -21 -141 26 71 50 0.35 -124
Net Cash From Continuing Investing Activities		 23 -14 36 -131 -21 -141 26 71 50 0.35 -124
Purchase of Property, Plant & Equipment		 -2.46 -2.59 -2.88 -1.94 -2.35 -2.11 -3.49 -2.68 -2.71 -5.13 -1.05
Purchase of Investments		 -75 -88 -55 -225 -130 -298 -110 -68 -103 -174 -256
Sale and/or Maturity of Investments		 100 77 93 96 111 160 139 142 156 180 133
Net Cash From Financing Activities		 1.70 0.01 1.62 238 46 201 1.47 0.01 1.16 236 20
Net Cash From Continuing Financing Activities		 1.70 0.01 1.62 238 46 201 1.47 0.01 1.16 236 20
Issuance of Common Equity		 0.78 - 1.27 238 43 199 1.25 - 0.98 235 20
Other Financing Activities, net		 0.93 0.01 0.36 0.22 3.04 1.45 0.22 0.01 0.18 1.25 0.38

Annual Balance Sheets for Nurix Therapeutics

This table presents Nurix Therapeutics' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2019 2020 2021 2022 2023 2024 2025
Period end date 11/30/2019 11/30/2020 11/30/2021 11/30/2022 11/30/2023 11/30/2024 11/30/2025
Total Assets		 44 396 477 417 356 669 688
Total Current Assets		 39 298 311 318 296 619 607
Cash & Equivalents		 35 119 81 64 55 110 247
Short-Term Investments		 2.90 162 215 245 233 500 346
Prepaid Expenses		 1.63 5.94 9.19 9.31 7.60 9.80 14
Plant, Property, & Equipment, net		 3.87 6.67 11 17 17 18 22
Total Noncurrent Assets		 0.82 91 154 81 43 32 59
Other Noncurrent Operating Assets		 0.32 0.35 17 17 36 32 59
Total Liabilities & Shareholders' Equity		 44 396 477 417 356 669 688
Total Liabilities		 54 106 134 113 155 142 149
Total Current Liabilities		 16 45 66 71 87 96 86
Accounts Payable		 1.60 3.41 6.65 5.06 6.40 11 11
Accrued Expenses		 4.93 - 15 22 25 38 55
Current Deferred Revenue		 9.61 33 41 38 48 38 18
Other Current Liabilities		 - - 3.85 5.53 7.49 8.01 2.82
Total Noncurrent Liabilities		 37 62 68 42 68 46 63
Noncurrent Deferred Revenue		 36 61 59 36 45 26 10
Other Noncurrent Operating Liabilities		 1.74 0.85 9.19 6.43 23 20 53
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 -58 290 342 304 200 527 539
Total Preferred & Common Equity		 -58 290 342 304 200 527 539
Preferred Stock		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity		 -58 290 342 304 200 527 539
Common Stock		 2.74 394 564 709 746 1,266 1,542
Retained Earnings		 -60 -104 -221 -401 -545 -739 -1,003
Accumulated Other Comprehensive Income / (Loss)		 -0.00 0.09 -0.61 -4.32 -0.66 0.15 0.11

Quarterly Balance Sheets for Nurix Therapeutics

This table presents Nurix Therapeutics' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q3 2022 Q1 2023 Q2 2023 Q3 2023 Q1 2024 Q2 2024 Q3 2024 Q1 2025 Q2 2025 Q3 2025 Q1 2026
Period end date 8/31/2022 2/28/2023 5/31/2023 8/31/2023 2/29/2024 5/31/2024 8/31/2024 2/28/2025 5/31/2025 8/31/2025 2/28/2026
Total Assets		 459 370 351 308 313 511 514 615 592 522 636
Total Current Assets		 355 288 290 268 251 450 456 564 515 441 554
Cash & Equivalents		 48 34 59 42 50 117 99 76 84 78 71
Short-Term Investments		 297 244 222 217 194 326 349 474 402 350 470
Prepaid Expenses		 10 11 8.84 7.10 6.98 7.08 7.99 14 11 12 14
Plant, Property, & Equipment, net		 17 18 18 17 18 19 17 18 19 20 22
Total Noncurrent Assets		 88 64 42 24 44 42 40 33 57 61 60
Other Noncurrent Operating Assets		 19 16 15 14 34 33 31 33 57 61 60
Total Liabilities & Shareholders' Equity		 459 370 351 308 313 511 514 615 592 522 636
Total Liabilities		 117 96 91 74 144 140 137 134 144 150 155
Total Current Liabilities		 68 65 72 61 88 81 86 90 76 82 92
Accounts Payable		 6.05 5.63 4.53 2.19 5.92 2.81 3.92 8.40 5.95 8.61 10
Accrued Expenses		 20 15 18 22 28 23 28 44 37 44 60
Current Deferred Revenue		 36 38 44 32 46 47 48 31 27 26 19
Other Current Liabilities		 5.50 5.56 5.58 5.36 7.31 7.93 6.55 6.64 5.24 3.79 3.20
Total Noncurrent Liabilities		 49 31 18 13 56 60 50 44 68 68 63
Noncurrent Deferred Revenue		 42 26 15 10 34 39 30 24 22 15 7.59
Other Noncurrent Operating Liabilities		 7.75 5.11 3.76 2.64 22 21 21 20 47 53 55
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 343 274 260 234 169 371 377 481 448 372 481
Total Preferred & Common Equity		 343 274 260 234 169 371 377 481 448 372 481
Preferred Stock		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity		 343 274 260 234 169 371 377 481 448 372 481
Common Stock		 701 719 728 738 756 1,002 1,057 1,276 1,286 1,297 1,571
Retained Earnings		 -355 -442 -466 -503 -587 -631 -680 -795 -839 -925 -1,090
Accumulated Other Comprehensive Income / (Loss)		 -3.74 -3.25 -1.90 -1.23 -0.35 -0.14 0.34 0.23 -0.02 0.12 0.06

Annual Metrics And Ratios for Nurix Therapeutics

This table displays calculated financial ratios and metrics derived from Nurix Therapeutics' official financial filings.

Metric 2019 2020 2021 2022 2023 2024 2025
Period end date 11/30/2019 11/30/2020 11/30/2021 11/30/2022 11/30/2023 11/30/2024 11/30/2025
Growth Metrics		 - - - - - - -
Revenue Growth		 0.00% -42.73% 66.95% 29.84% 99.31% -29.15% 53.95%
EBITDA Growth		 0.00% -212.79% -76.07% -56.80% 14.95% -41.58% -33.31%
EBIT Growth		 0.00% -192.24% -81.41% -55.97% 15.67% -37.38% -34.10%
NOPAT Growth		 0.00% -192.24% -81.41% -55.97% 15.67% -37.38% -34.10%
Net Income Growth		 0.00% -99.28% -171.02% -53.90% 20.19% -34.47% -36.62%
EPS Growth		 0.00% 58.12% 1.09% -35.90% 28.57% -8.68% -5.90%
Operating Cash Flow Growth		 0.00% -113.31% -105,356.25% -89.42% 49.09% -112.11% -44.55%
Free Cash Flow Firm Growth		 0.00% 0.00% -230.20% -129.50% 44.64% -94.34% -41.52%
Invested Capital Growth		 0.00% -53.82% -23.37% 23.49% -36.80% 12.91% 34.38%
Revenue Q/Q Growth		 0.00% 0.00% 2.43% -1.56% 12.21% -3.32% 0.35%
EBITDA Q/Q Growth		 0.00% 0.00% -17.65% -6.52% 1.84% -10.82% -6.32%
EBIT Q/Q Growth		 0.00% 0.00% -17.96% -6.20% 2.12% -9.98% -6.90%
NOPAT Q/Q Growth		 0.00% 0.00% -17.96% -6.20% 2.12% -9.98% -6.90%
Net Income Q/Q Growth		 0.00% 0.00% -17.89% -5.26% 3.20% -9.38% -8.04%
EPS Q/Q Growth		 0.00% 0.00% -5,360.00% 0.00% 2.93% 1.03% -3.04%
Operating Cash Flow Q/Q Growth		 0.00% -101.05% -14.11% -4.61% 44.27% -77.66% -8.28%
Free Cash Flow Firm Q/Q Growth		 0.00% 0.00% 0.00% -6.91% 43.53% -79.61% -8.15%
Invested Capital Q/Q Growth		 0.00% 0.00% -0.49% 2.44% -171.60% -2.38% 4.21%
Profitability Metrics		 - - - - - - -
Gross Margin		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
EBITDA Margin		 -64.25% -350.90% -370.08% -446.92% -190.72% -381.10% -330.00%
Operating Margin		 -71.46% -364.66% -396.26% -476.01% -201.41% -390.52% -340.16%
EBIT Margin		 -71.46% -364.66% -396.26% -476.01% -201.41% -390.52% -340.16%
Profit (Net Income) Margin		 -69.74% -242.66% -393.93% -466.93% -186.98% -354.85% -314.90%
Tax Burden Percent		 101.11% 67.80% 100.11% 100.00% 100.00% 100.14% 100.29%
Interest Burden Percent		 96.51% 98.14% 99.30% 98.09% 92.83% 90.74% 92.31%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)		 227.95% -30.80% -37.05% -55.84% -57.10% -53.22% -49.63%
Cash Return on Invested Capital (CROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Return on Assets (OROA)		 -50.48% -29.51% -27.00% -41.16% -40.15% -41.57% -42.09%
Return on Assets (ROA)		 -49.26% -19.64% -26.85% -40.37% -37.28% -37.77% -38.96%
Return on Common Equity (ROCE)		 1,382.10% -25.52% -37.05% -55.84% -57.10% -53.22% -49.63%
Return on Equity Simple (ROE_SIMPLE)		 37.60% -14.90% -34.24% -59.39% -71.80% -36.73% 0.00%
Net Operating Profit after Tax (NOPAT)		 -16 -45 -83 -129 -109 -149 -200
NOPAT Margin		 -50.02% -255.26% -277.38% -333.20% -140.99% -273.37% -238.11%
Net Nonoperating Expense Percent (NNEP)		 -16.05% 1.12% -8.71% -12.82% -10.59% -9.82% -10.73%
Return On Investment Capital (ROIC_SIMPLE)		 - - - -42.38% -54.14% -28.30% -37.12%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue		 26.76% 91.52% 104.88% 98.37% 55.73% 84.23% 62.80%
R&D to Revenue		 144.71% 373.14% 391.37% 477.64% 245.69% 406.30% 377.36%
Operating Expenses to Revenue		 171.46% 464.66% 496.26% 576.01% 301.41% 490.52% 440.16%
Earnings before Interest and Taxes (EBIT)		 -22 -65 -118 -184 -155 -213 -286
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -20 -63 -110 -173 -147 -208 -277
Valuation Ratios		 - - - - - - -
Price to Book Value (P/BV)		 0.00 5.71 3.76 1.92 1.50 2.97 2.52
Price to Tangible Book Value (P/TBV)		 0.00 5.71 3.76 1.92 1.50 2.97 2.52
Price to Revenue (P/Rev)		 6.72 92.93 43.22 15.12 3.92 28.71 16.19
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Revenue (EV/Rev)		 7.04 72.05 28.67 5.47 0.08 17.54 9.13
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 364.34 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - -
Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Financial Leverage		 4.02 -1.43 -1.26 -1.25 -1.33 -1.24 -1.13
Leverage Ratio		 -4.63 1.57 1.38 1.38 1.53 1.41 1.27
Compound Leverage Factor		 -4.47 1.54 1.37 1.36 1.42 1.28 1.18
Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 -506.30% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 606.30% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Altman Z-Score		 0.09 9.27 4.95 1.10 -1.50 5.03 3.08
Noncontrolling Interest Sharing Ratio		 -506.30% 17.17% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - - -
Current Ratio		 2.44 6.70 4.70 4.51 3.40 6.46 7.02
Quick Ratio		 2.34 6.31 4.55 4.38 3.31 6.36 6.86
Cash Flow Metrics		 - - - - - - -
Free Cash Flow to Firm (FCFF)		 0.00 -20 -65 -150 -83 -161 -228
Operating Cash Flow to CapEx		 36.40% -1.76% -1,490.28% -1,305.19% -968.52% -1,861.15% -1,781.64%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Efficiency Ratios		 - - - - - - -
Asset Turnover		 0.71 0.08 0.07 0.09 0.20 0.11 0.12
Accounts Receivable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 8.04 3.38 3.30 2.71 4.53 3.16 4.17
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Capital & Investment Metrics		 - - - - - - -
Invested Capital		 -48 -73 -91 -69 -95 -83 -54
Invested Capital Turnover		 -0.65 -0.29 -0.36 -0.48 -0.94 -0.61 -1.23
Increase / (Decrease) in Invested Capital		 0.00 -26 -17 21 -26 12 28
Enterprise Value (EV)		 219 1,284 853 211 6.36 957 766
Market Capitalization		 209 1,656 1,286 584 302 1,566 1,359
Book Value per Share		 ($17.53) $7.47 $7.67 $6.44 $4.13 $7.44 $7.01
Tangible Book Value per Share		 ($17.53) $7.47 $7.67 $6.44 $4.13 $7.44 $7.01
Total Capital		 -9.52 290 342 304 200 527 539
Total Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Long-Term Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt		 -38 -372 -433 -373 -295 -610 -593
Capital Expenditures (CapEx)		 1.65 4.55 5.66 12 8.40 9.27 14
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -15 -27 -51 -61 -79 -86 -73
Debt-free Net Working Capital (DFNWC)		 23 254 245 248 209 524 520
Net Working Capital (NWC)		 23 254 245 248 209 524 520
Net Nonoperating Expense (NNE)		 6.13 -2.25 35 52 35 44 64
Net Nonoperating Obligations (NNO)		 -38 -364 -433 -373 -295 -610 -593
Total Depreciation and Amortization (D&A)		 2.25 2.45 7.79 11 8.23 5.14 8.53
Debt-free, Cash-free Net Working Capital to Revenue		 -46.61% -152.93% -170.96% -158.82% -103.09% -157.75% -86.44%
Debt-free Net Working Capital to Revenue		 74.62% 1,424.78% 823.06% 641.50% 270.88% 959.75% 619.61%
Net Working Capital to Revenue		 74.62% 1,424.78% 823.06% 641.50% 270.88% 959.75% 619.61%
Earnings Adjustments		 - - - - - - -
Adjusted Basic Earnings per Share		 $0.00 ($2.76) ($2.73) ($3.71) ($2.65) ($2.88) ($3.05)
Adjusted Weighted Average Basic Shares Outstanding		 0.00 38.91M 44.74M 48.61M 54.34M 67.12M 86.67M
Adjusted Diluted Earnings per Share		 $0.00 ($2.76) ($2.73) ($3.71) ($2.65) ($2.88) ($3.05)
Adjusted Weighted Average Diluted Shares Outstanding		 0.00 38.91M 44.74M 48.61M 54.34M 67.12M 86.67M
Adjusted Basic & Diluted Earnings per Share		 $0.00 ($2.76) ($2.73) $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 0.00 15.67M 42.90M 47.27M 48.89M 75.89M 102.84M
Normalized Net Operating Profit after Tax (NOPAT)		 -16 -45 -83 -129 -109 -149 -200
Normalized NOPAT Margin		 -50.02% -255.26% -277.38% -333.20% -140.99% -273.37% -238.11%
Pre Tax Income Margin		 -68.97% -357.90% -393.49% -466.93% -186.98% -354.36% -314.00%
Debt Service Ratios		 - - - - - - -
EBIT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Payout Ratios		 - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Quarterly Metrics And Ratios for Nurix Therapeutics

This table displays calculated financial ratios and metrics derived from Nurix Therapeutics' official financial filings.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 8/31/2023 11/30/2023 2/29/2024 5/31/2024 8/31/2024 11/30/2024 2/28/2025 5/31/2025 8/31/2025 11/30/2025 2/28/2026
DEI Shares Outstanding		 - - - - - - - - - - 102,843,012.00
DEI Adjusted Shares Outstanding		 - - - - - - - - - - 102,843,012.00
DEI Earnings Per Adjusted Shares Outstanding		 - - - - - - - - - - -0.85
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 71.13% 123.49% 30.75% -60.58% -31.84% -12.37% 11.26% 264.34% -37.29% 2.21% -66.12%
EBITDA Growth		 12.52% 5.96% -6.58% -90.84% -41.54% -46.62% -43.99% 1.46% -63.52% -25.82% -45.60%
EBIT Growth		 14.35% 6.89% -5.28% -81.36% -36.49% -42.62% -39.02% 0.45% -67.34% -28.52% -47.14%
NOPAT Growth		 14.35% 6.89% -5.28% -81.36% -36.49% -42.62% -39.02% 0.45% -67.34% -28.52% -47.14%
Net Income Growth		 19.09% 10.19% -1.93% -83.49% -32.38% -39.55% -35.73% 2.43% -76.53% -33.60% -54.70%
EPS Growth		 24.44% 9.41% -1.33% -57.78% 1.47% 3.90% 11.84% 26.76% -53.73% -12.16% -17.91%
Operating Cash Flow Growth		 11.18% 170.32% 13.42% -114.98% -2.54% -282.66% -45.62% -59.08% -36.06% -39.14% -17.72%
Free Cash Flow Firm Growth		 -23.83% 88.76% 104.02% 98.33% 111.73% -824.26% -2,696.61% -8,794.76% -1,270.50% -50.53% -21.21%
Invested Capital Growth		 50.86% -36.80% -65.95% -67.96% -131.03% 12.91% 19.61% 53.34% 29.86% 34.38% 12.98%
Revenue Q/Q Growth		 -39.80% -17.91% 9.41% -27.09% 4.10% 5.53% 38.91% 138.75% -82.08% 71.99% -53.95%
EBITDA Q/Q Growth		 -56.72% -13.77% 0.65% -7.74% -16.23% -17.86% 2.43% 26.27% -92.88% 9.31% -12.90%
EBIT Q/Q Growth		 -49.49% -13.30% 0.25% -7.34% -12.51% -18.40% 2.77% 23.13% -89.12% 9.07% -11.31%
NOPAT Q/Q Growth		 -49.49% -13.30% 0.25% -7.34% -12.51% -18.40% 2.77% 23.13% -89.12% 9.07% -11.31%
Net Income Q/Q Growth		 -52.33% -13.45% 1.04% -7.29% -9.90% -19.60% 3.75% 22.87% -98.83% 9.49% -11.45%
EPS Q/Q Growth		 -51.11% -13.24% 1.30% 6.58% 5.63% -10.45% 9.46% 22.39% -98.08% 19.42% 4.82%
Operating Cash Flow Q/Q Growth		 -122.71% 164.88% -257.18% 5.35% -6.23% -15.59% -25.30% -3.40% 9.14% -18.21% -6.02%
Free Cash Flow Firm Q/Q Growth		 -23.14% 90.30% 137.62% -137.21% 963.75% -864.37% -5.69% -27.47% -13.67% 1.70% 14.89%
Invested Capital Q/Q Growth		 28.33% -171.60% 9.81% 4.34% 1.42% -2.38% 16.74% 44.48% -48.19% 4.21% -10.42%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
EBITDA Margin		 -207.25% -287.26% -260.84% -385.44% -430.34% -480.63% -337.58% -104.24% -1,122.14% -591.67% -1,450.69%
Operating Margin		 -216.67% -299.06% -272.65% -401.42% -433.83% -486.73% -340.67% -109.68% -1,157.65% -612.03% -1,479.45%
EBIT Margin		 -216.67% -299.06% -272.65% -401.42% -433.83% -486.73% -340.67% -109.68% -1,157.65% -612.03% -1,479.45%
Profit (Net Income) Margin		 -200.26% -276.77% -250.33% -368.39% -388.91% -440.75% -305.38% -98.66% -1,094.77% -576.13% -1,394.34%
Tax Burden Percent		 100.00% 100.00% 100.22% 100.20% 100.17% 100.01% 100.00% 101.78% 100.00% 100.00% 100.00%
Interest Burden Percent		 92.43% 92.55% 91.62% 91.59% 89.49% 90.54% 89.64% 88.37% 94.57% 94.13% 94.25%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)		 -51.60% -57.10% -65.37% -52.33% -57.96% -53.22% -64.16% -50.67% -65.35% -49.63% -61.40%
Cash Return on Invested Capital (CROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Return on Assets (OROA)		 -38.74% -59.62% -64.60% -58.05% -59.57% -51.81% -41.43% -17.58% -187.01% -75.73% -169.75%
Return on Assets (ROA)		 -35.80% -55.18% -59.31% -53.27% -53.40% -46.91% -37.14% -15.82% -176.86% -71.28% -159.98%
Return on Common Equity (ROCE)		 -51.60% -57.10% -65.37% -52.33% -57.96% -53.22% -64.16% -50.67% -65.35% -49.63% -61.40%
Return on Equity Simple (ROE_SIMPLE)		 -63.60% 0.00% -85.77% -44.51% -46.96% 0.00% -43.33% -46.32% 0.00% 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)		 -28 -32 -32 -34 -38 -45 -44 -34 -64 -58 -65
NOPAT Margin		 -151.67% -209.34% -190.86% -281.00% -303.68% -340.71% -238.47% -76.78% -810.36% -428.42% -1,035.61%
Net Nonoperating Expense Percent (NNEP)		 -2.63% -3.06% -3.40% -2.78% -2.95% -2.94% -3.07% -2.05% -5.07% -3.34% -4.11%
Return On Investment Capital (ROIC_SIMPLE)		 - -15.83% - - - -8.59% -9.15% -7.56% -17.18% -10.80% -13.46%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue		 57.52% 71.11% 71.14% 96.84% 93.09% 80.68% 63.16% 32.42% 166.70% 100.52% 233.69%
R&D to Revenue		 259.14% 327.94% 301.51% 404.58% 440.75% 506.05% 377.52% 177.27% 1,090.96% 611.50% 1,345.76%
Operating Expenses to Revenue		 316.67% 399.06% 372.65% 501.42% 533.83% 586.73% 440.67% 209.68% 1,257.65% 712.03% 1,579.45%
Earnings before Interest and Taxes (EBIT)		 -40 -45 -45 -49 -55 -65 -63 -48 -91 -83 -92
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -38 -44 -43 -47 -54 -64 -62 -46 -89 -80 -91
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 1.75 1.50 3.55 2.09 4.31 2.97 2.44 1.81 1.92 2.52 3.42
Price to Tangible Book Value (P/TBV)		 1.75 1.50 3.55 2.09 4.31 2.97 2.44 1.81 1.92 2.52 3.42
Price to Revenue (P/Rev)		 5.97 3.92 7.41 12.43 28.77 28.71 20.78 9.17 8.53 16.19 22.88
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Revenue (EV/Rev)		 2.05 0.08 4.26 5.16 20.66 17.54 11.04 3.67 3.41 9.13 15.35
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Financial Leverage		 -1.18 -1.33 -1.31 -1.21 -1.19 -1.24 -1.24 -1.15 -1.18 -1.13 -1.13
Leverage Ratio		 1.33 1.53 1.54 1.37 1.35 1.41 1.43 1.35 1.38 1.27 1.30
Compound Leverage Factor		 1.23 1.42 1.41 1.25 1.20 1.28 1.28 1.19 1.31 1.20 1.23
Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Altman Z-Score		 1.62 -0.48 0.28 2.26 5.89 5.76 4.11 2.16 0.78 4.05 4.45
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 4.36 3.40 2.86 5.57 5.28 6.46 6.26 6.82 5.35 7.02 6.01
Quick Ratio		 4.24 3.31 2.78 5.49 5.19 6.36 6.11 6.68 5.21 6.86 5.86
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 -64 -6.22 2.34 -0.87 7.52 -58 -61 -77 -88 -87 -74
Operating Cash Flow to CapEx		 -1,672.75% 1,032.46% -1,454.61% -2,049.82% -1,797.06% -2,315.96% -1,752.86% -2,361.16% -2,116.75% -1,322.00% -6,881.72%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 0.18 0.20 0.24 0.14 0.14 0.11 0.12 0.16 0.16 0.12 0.11
Accounts Receivable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 4.15 4.53 4.55 3.36 3.35 3.16 3.11 4.74 4.46 4.17 3.58
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 -35 -95 -86 -82 -81 -83 -69 -38 -57 -54 -60
Invested Capital Turnover		 -1.29 -0.94 -1.18 -0.95 -0.98 -0.61 -0.73 -1.47 -1.22 -1.23 -1.12
Increase / (Decrease) in Invested Capital		 36 -26 -34 -33 -46 12 17 44 24 28 8.92
Enterprise Value (EV)		 141 6.36 345 322 1,166 957 623 325 285 766 1,102
Market Capitalization		 410 302 599 774 1,623 1,566 1,172 810 714 1,359 1,642
Book Value per Share		 $4.85 $4.13 $3.07 $7.54 $5.85 $7.44 $6.34 $5.87 $4.87 $7.01 $4.68
Tangible Book Value per Share		 $4.85 $4.13 $3.07 $7.54 $5.85 $7.44 $6.34 $5.87 $4.87 $7.01 $4.68
Total Capital		 234 200 169 371 377 527 481 448 372 539 481
Total Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Long-Term Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt		 -269 -295 -254 -453 -458 -610 -550 -486 -429 -593 -541
Capital Expenditures (CapEx)		 2.46 2.59 2.88 1.94 2.35 2.11 3.49 2.68 2.71 5.13 1.05
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -52 -79 -81 -74 -78 -86 -76 -46 -71 -73 -79
Debt-free Net Working Capital (DFNWC)		 206 209 163 369 370 524 474 440 358 520 462
Net Working Capital (NWC)		 206 209 163 369 370 524 474 440 358 520 462
Net Nonoperating Expense (NNE)		 8.97 10 9.86 11 11 13 12 9.64 22 20 22
Net Nonoperating Obligations (NNO)		 -269 -295 -254 -453 -458 -610 -550 -486 -429 -593 -541
Total Depreciation and Amortization (D&A)		 1.74 1.79 1.96 1.93 0.44 0.81 0.57 2.40 2.80 2.76 1.80
Debt-free, Cash-free Net Working Capital to Revenue		 -76.37% -103.09% -99.70% -118.29% -138.78% -157.75% -134.65% -52.12% -84.33% -86.44% -109.42%
Debt-free Net Working Capital to Revenue		 300.91% 270.88% 201.94% 592.97% 655.30% 959.75% 839.67% 497.52% 428.09% 619.61% 643.91%
Net Working Capital to Revenue		 300.91% 270.88% 201.94% 592.97% 655.30% 959.75% 839.67% 497.52% 428.09% 619.61% 643.91%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 ($0.68) ($0.77) ($0.76) ($0.71) ($0.67) ($0.74) ($0.67) ($0.52) ($1.03) ($0.83) ($0.79)
Adjusted Weighted Average Basic Shares Outstanding		 54.39M 54.34M 54.90M 62.38M 72.78M 67.12M 83.56M 83.88M 84.16M 86.67M 110.07M
Adjusted Diluted Earnings per Share		 ($0.68) ($0.77) ($0.76) ($0.71) ($0.67) ($0.74) ($0.67) ($0.52) ($1.03) ($0.83) ($0.79)
Adjusted Weighted Average Diluted Shares Outstanding		 54.39M 54.34M 54.90M 62.38M 72.78M 67.12M 83.56M 83.88M 84.16M 86.67M 110.07M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 48.50M 48.89M 49.15M 64.41M 70.84M 75.89M 76.24M 76.45M 76.88M 102.84M 103.41M
Normalized Net Operating Profit after Tax (NOPAT)		 -28 -32 -32 -34 -38 -45 -44 -34 -64 -58 -65
Normalized NOPAT Margin		 -151.67% -209.34% -190.86% -281.00% -303.68% -340.71% -238.47% -76.78% -810.36% -428.42% -1,035.61%
Pre Tax Income Margin		 -200.26% -276.77% -249.79% -367.65% -388.26% -440.69% -305.38% -96.93% -1,094.77% -576.13% -1,394.34%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Financials Breakdown Chart

Key Financial Trends

Nurix Therapeutics (NASDAQ: NRIX) has delivered a pattern of substantial operating losses and a high, ongoing R&D burn over the last four years, while intermittently raising capital to fund its cash needs. Below is a concise, investor-oriented synthesis drawn from Nurix’s quarterly income statements, cash flow statements, and balance sheets covering the period through Q4 2025.

  • Q4 2025 equity raise: Nurix issued common stock for about $234.8 million, significantly boosting liquidity.
  • Strong financing inflow in Q4 2025: Net cash from continuing financing activities was about $236.0 million, helping to fund ongoing operations and investments.
  • Liquidity cushion in 2025: Cash and cash equivalents generally remained in the roughly $75–85 million range across 2025, supported by equity raises and financing activity.
  • Investing activity infusions: Several quarters show meaningful net cash inflows from investing activities (e.g., about $50.5 million in Q3 2025 and about $71.5 million in Q2 2025), largely from asset sales rather than core operations.
  • Leverage and liabilities: Nurix carries a modest balance sheet with total liabilities typically in the mid-$140s to low-$150s millions and no material debt burden evident in the provided periods.
  • Ongoing R&D burn: Research & development expenses remain the dominant operating outlay, roughly $70–$86 million per quarter in 2025, well outpacing quarterly revenue in most periods.
  • Net income is consistently negative: 2025 Q4 net income around -$78.2 million (EPS -0.83); 2025 Q3 around -$86.4 million (EPS -1.03); and sizable losses in prior quarters and years.
  • Operating cash flow remains negative: Net cash from continuing operating activities was about -$67.8 million in Q4 2025, -$57.4 million in Q3 2025, and similarly negative in other recent quarters, signaling ongoing cash burn from operations.
  • Cumulative losses have eroded equity: Retained earnings were deeply negative (approximately -$925 million by Q4 2025), reflecting multi-year losses despite equity financing activity.
  • Earnings per share: Both basic and diluted earnings per share remained negative across the periods (Q4 2025 EPS -0.83; Q3 2025 EPS -1.03), underscoring ongoing profitability challenges despite capital raises.
05/14/26 07:15 PM ETAI Generated. May Contain Errors.

Nurix Therapeutics Financials - Frequently Asked Questions

According to the most recent income statement we have on file, Nurix Therapeutics' fiscal year ends in November. Their fiscal year 2025 ended on November 30, 2025.

Nurix Therapeutics' net income appears to be on an upward trend, with a most recent value of -$264.46 million in 2025, rising from -$21.70 million in 2019. The previous period was -$193.57 million in 2024. Check out Nurix Therapeutics' forecast to explore projected trends and price targets.

Nurix Therapeutics' total operating income in 2025 was -$285.67 million, based on the following breakdown:
  • Total Gross Profit: $83.98 million
  • Total Operating Expenses: $369.65 million

Over the last 6 years, Nurix Therapeutics' total revenue changed from $31.12 million in 2019 to $83.98 million in 2025, a change of 169.9%.

Nurix Therapeutics' total liabilities were at $149.39 million at the end of 2025, a 4.9% increase from 2024, and a 178.9% increase since 2019.

In the past 6 years, Nurix Therapeutics' cash and equivalents has ranged from $34.82 million in 2019 to $246.96 million in 2025, and is currently $246.96 million as of their latest financial filing in 2025.

Over the last 6 years, Nurix Therapeutics' book value per share changed from -17.53 in 2019 to 7.01 in 2025, a change of -140.0%.


Related Companies

Financial statements for NASDAQ:NRIX last updated on 4/12/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.
From Our Partners
Trump's gold order: the announcement they won't put on the front page
On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...
Reagan Gold Group | Sponsoredtc pixel
Iran's New Leader Just Said Something That Should Terrify Every American
Iran's Supreme Leader has declared the Strait of Hormuz closed as leverage against the U.S. - and with 40% of ...
American Alternative | Sponsoredtc pixel
Peptide Company Lands Exclusive MMA Wellness Partnership
A publicly traded peptide company just signed an exclusive partnership with a NYSE-listed MMA media platform t...
The Tomorrow Investor | Sponsoredtc pixel
CODE RED: AI Meltdown Imminent?
After correctly predicting the 2008 and 2020 stock market meltdowns, I believe this AI company is about to tri...
Paradigm Press | Sponsoredtc pixel
I’m sounding the alarm
Meta is cutting 10% of its workforce. Microsoft offered voluntary retirement to 7% of U.S. employees. Oracle, ...
Porter & Company | Sponsoredtc pixel
Your book is inside
The "Sucker's Bet" Most New Options Traders Fall For Most people who try options lose money the same way. ...
Profits Run | Sponsoredtc pixel
BlackRock, JPMorgan, and Goldman are all stock piling the same asset… are you?
BlackRock, JPMorgan, Goldman Sachs, Fidelity, ARK Invest and Andreessen Horowitz are all buying the same asset...
Awesomely, LLC | Sponsoredtc pixel
Distracted Americans set to miss out on quadrillions
Technology expert and Washington D.C. insider Jeff Brown - who identified Bitcoin, Tesla, and Nvidia early - s...
Brownstone Research | Sponsoredtc pixel